Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TTC23L antisense RNA 1 (TTC23L-AS1) is a gene encoding a long non-coding antisense RNA that is transcribed in the opposite direction to the TTC23L gene on chromosome 17 in humans. Antisense lncRNAs like TTC23L-AS1 are known to regulate gene expression through mechanisms such as chromatin remodeling, hybridization to target mRNAs, and modulation of transcription at their loci of origin or at distant sites. Antisense RNAs can modulate key cellular processes, including epigenetic silencing and gene activation, and are being explored for their potential relevance to diseases such as cancer. However, there is no current evidence implicating TTC23L-AS1 as a therapeutic target or druggable molecule. TTC23L-AS1 is classified as a long non-coding RNA based on its annotation in major gene databases, such as Ensembl, and has not been identified as encoding a protein or functioning as a traditional therapeutic receptor or enzyme. The biological function of TTC23L-AS1, like many antisense RNAs, is likely related to the regulation of gene expression, but specific roles and disease associations remain to be clarified.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TTC23L antisense RNA 1 (TTC23L-AS1).